Europe’s share of clinical trials falls 13.5% as Asia’s research footprint expands

The latest data show a 13.5% drop in the number of clinical trials authorized in the EU and EEA compared with pre-pandemic levels.

At the same time, Asian countries have increased their share of global clinical research, capturing a larger proportion of new studies.

The shift suggests sponsors are seeking faster patient recruitment and lower costs in Asia, raising concerns for European research ecosystems and potential impacts on local biotech investment.